迈威生物(688062) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the current period is CNY 9,550,011.97, representing a year-on-year increase of 1.92%[3] - The net profit attributable to shareholders of the listed company is CNY -259,761,460.08, with a year-to-date loss of CNY -673,286,515.50[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY -262,156,441.27 for the current period, with a year-to-date loss of CNY -677,691,454.78[3] - Basic and diluted earnings per share for the current period are both CNY -0.65, with a year-to-date figure of CNY -1.68[3] - The total revenue for the year-to-date period increased by 387.22%, primarily due to a licensing agreement with DISC MEDICINE, INC. and sales of the drug Mai Li Shu®[14] - The company reported a net loss of CNY -668,496,734.05 attributable to shareholders, slightly improved from CNY -686,548,898.54 in the previous year[26] - The total comprehensive income for the period was CNY -671,829,240.37, slightly better than CNY -686,570,753.60 in the previous year[26] - The net profit for the first three quarters of 2023 was a loss of ¥676,619,021.82, compared to a loss of ¥692,443,802.24 in the same period last year, showing an improvement of about 2.4%[46] - The company reported a total profit of ¥-676,041,100.24, which is an improvement from ¥-692,443,802.24 in the previous year, indicating a positive change of approximately 2.4%[46] Cash Flow and Liquidity - The cash flow from operating activities is CNY -562,458,858.54 year-to-date[3] - The net cash flow from operating activities was negative at CNY -562,458,858.54, worsening from CNY -507,698,762.84 year-over-year[27] - Cash received from sales and services increased to CNY 90,276,727.22, a substantial rise from CNY 997,350.00 in the same period last year[27] - The cash and cash equivalents at the end of the period decreased to CNY 1,809,447,557.54 from CNY 2,715,179,589.74, reflecting a decline of approximately 33.4%[28] - The company recorded a total cash outflow from investing activities of CNY 732,547,641.13, compared to CNY 1,055,422,462.69 in the previous year[27] - The financing activities generated a net cash inflow of CNY 328,498,573.88, a significant decrease from CNY 3,589,758,174.71 in the previous year[28] - The company received CNY 280,000,000.00 from the recovery of investments, down from CNY 590,000,000.00 year-over-year[27] - Cash and cash equivalents decreased to approximately ¥1.76 billion from ¥2.49 billion year-over-year[40] Assets and Liabilities - The total assets of the company as of September 30, 2023, amount to CNY 4,450,532,150.65, compared to CNY 4,619,475,225.93 at the end of the previous period[19] - The company's inventory as of September 30, 2023, is CNY 152,847,845.26, an increase from CNY 79,049,785.33[19] - The total liabilities increased to CNY 1,536,379,427.68, up from CNY 1,108,864,451.65, representing a growth of approximately 38.5% year-over-year[20] - The company's total equity showed a significant negative balance in retained earnings, amounting to CNY -3,371,203,295.52, compared to CNY -2,697,916,780.02 in the previous year[20] - Total assets as of September 30, 2023, were ¥4.45 billion, a decrease of 3.66% from ¥4.62 billion at the end of the previous year[32] - Equity attributable to shareholders of the listed company decreased by 16.87% to ¥2.92 billion from ¥3.52 billion[32] - The total liabilities and equity amounted to ¥4.45 billion, down from ¥4.62 billion year-over-year[44] Research and Development - Research and development expenses decreased by 30.03% in the current period, with the ratio of R&D expenses to operating revenue decreasing by 734.81 percentage points[15] - Total R&D investment amounted to approximately ¥153.68 million, a decrease of 30.03% year-over-year from ¥494.11 million[32] - R&D investment as a percentage of operating revenue was 1,609.23%, down 734.81 percentage points from the previous year's 496.54%[32] - Research and development expenses were ¥494,110,768.85, slightly decreased from ¥535,195,015.88 in 2022, reflecting a reduction of approximately 7.7%[45] Other Income and Expenses - The company reported non-operating income of approximately ¥2.39 million for the current period, with a total of ¥4.40 million from the beginning of the year to the reporting period[33] - The company received government subsidies totaling approximately ¥1.32 million during the current period, contributing to its non-operating income[33] - The company recorded an investment income of ¥1,366,910.34, up from ¥300,336.67 in the previous year, representing a growth of approximately 354.5%[46] - The financial expenses showed a net income of ¥-26,622,479.36, compared to ¥-23,401,724.74 in the previous year, indicating an increase in financial costs[45] - The company experienced a credit impairment loss of ¥965,231.48, contrasting with a gain of ¥-1,015,242.53 in the previous year, reflecting a significant change in credit quality[46] - The company’s sales expenses surged to ¥161,278,252.49, compared to ¥67,224,930.24 in the previous year, marking an increase of approximately 139.9%[45] - Other comprehensive income after tax was ¥4,789,781.45, compared to ¥5,873,048.64 in the previous year, showing a decrease of about 18.5%[46]